The Latest Cardiac and Vascular News
– First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%. – BD’s COVID-19 testing sales of $867 million contributed 20.5 percentage points to revenue growth on a reported basis. […]
– There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomes – Compared with standard approaches, the BD vascular care solution […]
Polen to Succeed Vince Forlenza Effective April 28 FRANKLIN LAKES, N.J., Jan. 26, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of […]
– Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis. – BD’s COVID-19 testing sales totaled more than $440 million in the fourth fiscal quarter. – Fiscal fourth quarter GAAP EPS were $0.36. Non-GAAP […]
Patrick Kaltenbach appointed chief technology officer Dave Hickey promoted to president, Life Sciences segment FRANKLIN LAKES, N.J., Oct. 22, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and […]
– As reported, revenues of $4.225 billion increased 1.6 percent. – On a currency-neutral basis, revenues increased 2.5 percent. – As reported, diluted earnings per share of $0.87 decreased 57.6 percent. – As adjusted, diluted earnings per share of $2.65 […]
FRANKLIN LAKES, N.J., Sept. 28, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a company-initiated, independent analysis of the LUTONIX® 035 Drug Coated Balloon (DCB) femoropopliteal clinical program in the Journal of the American […]
FRANKLIN LAKES, N.J., Sept. 26, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020, following the company’s annual meeting of shareholders. Forlenza […]
– As reported, revenues of $4.350 billion increased 1.7 percent. – On a comparable, currency-neutral basis, revenues increased 5.7 percent. – As reported, diluted earnings per share of $1.51 decreased 25.6 percent. – As adjusted, diluted earnings per share of […]
FRANKLIN LAKES, N.J., June 20, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee […]
